A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
28 10 2022
Historique:
received: 05 09 2022
revised: 15 10 2022
accepted: 20 10 2022
entrez: 10 11 2022
pubmed: 11 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We assessed the modified Ashworth scale (MAS) of the ankle joint, the mobility scores of Functional Independence Measure (FIM), and the grip power of the unaffected hand before and after injecting 300 units of BOTOX or A2NTX into calf muscles. The procedure was done in a blinded manner for the patient, the injecting physician, and the examiner. Stroke patients with chronic spastic hemiparesis (15 for A2NTX and 16 for BOTOX) were enrolled, and 11 for A2NTX and 13 for BOTOX (MAS of ankle; > or = 2) were entered for the MAS study. Area-under-curves of changes in MAS (primary outcome) were greater for A2NTX by day 30 (

Identifiants

pubmed: 36355989
pii: toxins14110739
doi: 10.3390/toxins14110739
pmc: PMC9697926
pii:
doi:

Substances chimiques

Botulinum Toxins, Type A EC 3.4.24.69
Neuromuscular Agents 0
Neurotoxins 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Toxins (Basel). 2021 Nov 22;13(11):
pubmed: 34822610
FEBS Lett. 2011 Jan 3;585(1):199-206
pubmed: 21126520
Curr Med Res Opin. 2010 Aug;26(8):1983-92
pubmed: 20569068
Front Neurol. 2014 Jun 23;5:98
pubmed: 25002857
J Pharmacol Sci. 2011;117(4):275-85
pubmed: 22123262
Hokkaido Igaku Zasshi. 1995 Jan;70(1):19-28
pubmed: 7744367
Toxicon. 2010 Dec;56(8):1315-26
pubmed: 20674584
Tremor Other Hyperkinet Mov (N Y). 2012;2:
pubmed: 23440162
Front Neurol. 2022 Mar 17;13:832937
pubmed: 35370917
Cochrane Database Syst Rev. 2017 Dec 12;12:CD003633
pubmed: 29230798
J Neurol. 2020 May;267(5):1340-1347
pubmed: 31960136
Neuroscience. 2017 Jun 3;352:155-169
pubmed: 28389376
J Rehabil Med. 2005 Mar;37(2):75-82
pubmed: 15788341
Toxins (Basel). 2018 Dec 13;10(12):
pubmed: 30551641
mBio. 2018 Mar 27;9(2):
pubmed: 29588398
Muscle Nerve. 2004 May;29(5):628-44
pubmed: 15116366
Toxicon. 2014 Apr;81:32-6
pubmed: 24495439
Arch Phys Med Rehabil. 1993 May;74(5):531-6
pubmed: 8489365
Infect Immun. 2016 Dec 29;85(1):
pubmed: 27795365
JAMA. 1992 Jun 17;267(23):3149
pubmed: 1593726
Spinal Cord. 1999 Jan;37(1):58-61
pubmed: 10025698
J Pediatr Rehabil Med. 2020;13(2):201-204
pubmed: 32568126
Phys Ther. 1987 Feb;67(2):206-7
pubmed: 3809245
Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Apr;268(2):220-7
pubmed: 3293334
Toxicon. 2011 Jan;57(1):93-9
pubmed: 21029745
Drugs R D. 2015 Mar;15(1):1-9
pubmed: 25559581
Toxins (Basel). 2022 Apr 27;14(5):
pubmed: 35622555
Ann Dermatol Venereol. 2009 May;136 Suppl 4:S77-85
pubmed: 19576490
Pharmacotherapy. 2013 Mar;33(3):304-18
pubmed: 23400888
J Neural Transm (Vienna). 2019 Aug;126(8):1047-1050
pubmed: 31168666
Toxicon. 2015 Dec 1;107(Pt A):85-8
pubmed: 26394198
Microbiol Immunol. 1995;39(10):767-74
pubmed: 8577267
J Neurol. 2010 Aug;257(8):1330-7
pubmed: 20358216
Anal Bioanal Chem. 2015 Jul;407(19):5559-70
pubmed: 26038189
Toxins (Basel). 2010 May;2(5):978-97
pubmed: 22069621
J Cosmet Dermatol. 2022 Jan;21(1):137-141
pubmed: 34897934
J Physiol. 2013 Feb 15;591(4):1031-43
pubmed: 23109108
PM R. 2010 Apr;2(4):282-4
pubmed: 20430330
Toxins (Basel). 2018 May 18;10(5):
pubmed: 29783676
Mov Disord. 1995 Jul;10(4):466-71
pubmed: 7565828
Acta Med Port. 2020 Nov 2;33(11):761-764
pubmed: 31759399
Toxicon. 2018 Oct;153:114-119
pubmed: 30193802

Auteurs

Ryuji Kaji (R)

Department of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
National Hospital Organization Utano Hospital, Kyoto 616-8255, Japan.

Ai Miyashiro (A)

Department of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.

Nori Sato (N)

Department of Rehabilitation Medicine, Tokushima University Hospital, Tokushima 770-8503, Japan.

Taiki Furumoto (T)

Department of Rehabilitation Medicine, Tokushima University Hospital, Tokushima 770-8503, Japan.

Toshiaki Takeuchi (T)

Department of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.
National Hospital Organization Utano Hospital, Kyoto 616-8255, Japan.

Ryosuke Miyamoto (R)

Department of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.

Tomoko Kohda (T)

Laboratory of Epidemiology, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka 598-8531, Japan.

Yuishin Izumi (Y)

Department of Clinical Neuroscience, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan.

Shunji Kozaki (S)

Laboratory of Epidemiology, Graduate School of Veterinary Sciences, Osaka Metropolitan University, Osaka 598-8531, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH